-
Views
-
Cite
Cite
Rahul S Dalal, Lindsay M Clarke, Alex Carlin, Heidy Cabral, Jessica R Allegretti, Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis, Inflammatory Bowel Diseases, Volume 31, Issue 4, April 2025, Pages 1174–1177, https://doi.org/10.1093/ibd/izae215
- Share Icon Share
Lay Summary
In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.
© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/pages/standard-publication-reuse-rights)
Subject
Treatment
Issue Section:
Clinical Brief Report
You do not currently have access to this article.